Volume 16, Issue 64 (12-2026)                   NCMBJ 2026, 16(64): 44-60 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohebifar A, Safinejad K, Hoveida R. The Role of Polygala tenuifolia Extract in Ferroptosis Induction in Breast Cancer Cells through Modulation of mTOR, p53, GPX4, and TGF-β. , NCMBJ. 2026; 16 (64) :44-60
URL: http://ncmbjpiau.ir/article-1-1898-en.html
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Borujerd Branch, Borujerd, Iran
Abstract:   (40 Views)
| Extended Abstract
Background and Aim: Breast cancer remains the most frequently diagnosed malignancy among women and a leading cause of cancer-related mortality worldwide. The triple-negative subtype (TNBC), lacking ER, PR, and HER2, responds poorly to conventional therapies and has an unfavorable prognosis, underscoring the need for novel, effective, and low-toxicity strategies. Ferroptosis is an iron-dependent, non-apoptotic form of programmed cell death driven by lipid peroxide and ROS accumulation in membranes. Unlike apoptosis, necroptosis, or autophagy, it results from oxidative damage to membrane phospholipids and can eliminate cancer cells that evade anti-apoptotic pathways. Its key regulators include GPX4, p53, mTOR, and TGF-β. GPX4, the principal endogenous inhibitor, reduces lipid peroxides via glutathione, and its downregulation triggers ferroptosis. p53 suppresses cystine transporters such as SLC7A11, lowering glutathione and promoting ferroptosis, while mTOR inhibition also facilitates ferroptotic death. Natural compounds and plant extracts have recently attracted attention as ferroptosis modulators. Polygala tenuifolia, used in Chinese medicine as a memory enhancer and anxiolytic, contains tenuifolin, onjisaponins, and senegenin with antioxidant, anti-inflammatory, and anticancer properties. This study investigated the effect of Polygala tenuifolia extract on ferroptosis induction in MCF-7 cells via modulation of mTOR, p53, GPX4, and TGF-β.
Materials and Methods: Polygala tenuifolia was obtained from the local market of Xihu, Hangzhou, Zhejiang, China, and authenticated at the Department of Plant Medicine, Zhejiang University (herbarium No. PTV-001). The plant was washed, dried at 25 ± 1 °C, and powdered. Extraction was performed by maceration in 70% ethanol for 72 hours with magnetic stirring; the extract was filtered, concentrated under low pressure, and stored at −20 °C. MCF-7 (Luminal A; ER+, PR+, HER2−) and normal MCF-10A cells were obtained from the Pasteur Institute of Iran and cultured in RPMI-1640 with 10% FBS and 1% penicillin/streptomycin at 37 °C, 5% CO₂, with medium changed every two days. Viability was assessed by MTT assay after 48-hour treatment with 25–200 µg/mL extract, measuring absorbance at 540 nm. Lipid peroxidation was evaluated by BODIPY-C11 staining and flow cytometry, using the green/red fluorescence ratio as an index. GPX4, P53, TGF-β1, and mTOR expression was analyzed by Western blotting with RIPA buffer, SDS-PAGE, and PVDF membranes; membranes were blocked with 0.5% BSA and incubated with primary antibodies (GPX4, CST 2972, 1:1000; p53, CST 52455, 1:1000; mTOR, Abcam ab26, 1:1000; TGF-β1, Abcam ab9758, 1:5000), followed by HRP-conjugated secondary antibody, with β-actin as loading control and ImageJ for signal analysis. All experiments were performed in triplicate; data were analyzed with SPSS v24 using one-way ANOVA, Tukey's post-hoc test, and multiple linear regression (p < 0.05; mean ± SD).
Results: GC-MS identified tenuifoloside A (23.1%), senegenin (17.8%), polygalacic acid (14.6%), methyl salicylate (9.7%), oleic acid (7.9%), linoleic acid (6.5%), palmitic acid (5.2%), stearic acid (4.1%), β-sitosterol (3.3%), and phytol (2.6%), mainly fatty acids, saponins, and phenolics. Retention times ranged from 12 to 26 minutes, with low-molecular-weight compounds eluting earlier and high-molecular-weight compounds appearing later, consistent with gas chromatography principles. The extract reduced MCF-7 viability dose-dependently (35.2% at 100 µg/mL; p < 0.001) without significantly affecting MCF-10A cells (88.9%), indicating selective cytotoxicity, whereas RSL3 reduced viability in both lines. Lipid peroxidation increased 2.41-fold versus controls (p < 0.001). GPX4 expression decreased by 62% (0.38 ± 0.06-fold; p = 0.004) and mTOR decreased (0.66 ± 0.14-fold; p = 0.021), while P53 increased 1.82-fold (p = 0.012) and TGF-β increased 2.10-fold (p = 0.009). Regression analysis showed reduced GPX4 (β = +0.61) and increased lipid peroxidation (β = −0.58), along with p53 (β = −0.42), TGF-β (β = −0.36), and mTOR (β = +0.33), as the most influential variables, explaining 93.1% of variance (R² = 0.931). Morphologically, treated cells became spherical, smaller, and less adherent, with membrane disruption and loss of colony organization, consistent with ferroptosis.
Conclusion: Polygala tenuifolia extract induces ferroptosis in MCF-7 cells by inhibiting the antioxidant system and modulating key cellular components. Downregulation of GPX4 and mTOR, together with upregulation of P53 and TGF-β, indicates suppressed antioxidant defense, enhanced oxidative stress, and activated ferroptotic pathways. The presence of polygalacic acid (an mTOR inhibitor and ferroptosis inducer) and methyl salicylate (a P53 regulator) provides a mechanistic basis. These results align with studies showing that curcumin and baicalin sensitize cancer cells to ferroptosis via GPX4 targeting, and that p53 activation with SLC7A11 inhibition and mTOR suppression facilitates ferroptosis. Unlike synthetic inducers such as erastin and RSL3, this plant-derived extract may offer lower toxicity to normal cells, making it a promising candidate for targeted herbal therapeutics.
Full-Text [PDF 1072 kb]   (29 Downloads)    
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2026/11/17 | Accepted: 2026/12/1 | Published: 2026/12/1

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb